Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MuGard website launched
www.mugard.com
ACCP Receives Initial Purchase Order for MuGard in North America
$700,000 of MuGard sold to BioScrip for online inventory
http://www.prnewswire.com/news-releases/access-pharmaceuticals-receives-initial-purchase-order-for-mugard-in-north-america-102851504.html
$700,000 in MuGard sold to BioScrip Today.
http://www.prnewswire.com/news-releases/access-pharmaceuticals-receives-initial-purchase-order-for-mugard-in-north-america-102851504.html
People are coming out of the woodwork to hate on the company. Including someone who admitted that they are looking for something to do between trades to help a friend. Pretty Sad.
Access Pharma's MuGard could help Michael Douglas
http://www.otcshowcase.com/?p=891
Bear with me.
Doctors sign up, set up practices, invite more colleagues to do the same, in time = Slow & Steady
Subscription revenue flows into the company, increasing the value of the stock = Wins The Race.
Slow & Steady, Wins The Race.
That Was Easy.
Access Pharmaceuticals to present at Annual Rodman & Renshaw Global Investment Conference in NYC
http://markets.financialcontent.com/gatehouse.rrstar/news/read?GUID=14613768
Is the stock supposed to explode in the first 2 hours of launch?
If you would be so kind as to indulge me in this story that was written thousands of years ago:
There once was a speedy hare who bragged about how fast he could run. Tired of hearing him boast, Slow and Steady, the tortoise, challenged him to a race. All the animals in the forest gathered to watch.
Hare ran down the road for a while and then and paused to rest. He looked back at Slow and Steady and cried out, "How do you expect to win this race when you are walking along at your slow, slow pace?"
Hare stretched himself out alongside the road and fell asleep, thinking, "There is plenty of time to relax."
Slow and Steady walked and walked. He never, ever stopped until he came to the finish line.
The animals who were watching cheered so loudly for Tortoise, they woke up Hare.
Hare stretched and yawned and began to run again, but it was too late. Tortoise was over the line.
After that, Hare always reminded himself, "Don't brag about your lightning pace, for Slow and Steady won the race!"
iMedicor Launches Phase I of The National Healthcare Communications Network
USA MCO, Physicians Alliance of America, and PASHealth Join iMedicor to Offer New Subscription Service Priced at $24.95 per Month
NANUET, NY--(Marketwire - September 8, 2010) - iMedicor (OTCBB: VMCI) announced today the launch of The National Healthcare Communications Network. The Network will allow the transport of HIPAA-compliant secure messaging with attachments (medical records, files and images), a social portal that encourages peer collaboration and expansion of inbound and outbound referrals, and access to the largest collection of certified Continuing Medical Education programs, staff and skill level development programs and product/device-specific educational resources.
The initial marketing of this service will begin immediately to select groups within the total targeted base of over 500,000 physicians and their practices, all of whom are registered users of iMedicor's network partners. The Network will serve as a secure, Internet-based upgrade to the communications between the various user bases of those partners. Regular subscription licensing is priced at $24.95 per month per practice for unlimited use of the Network. Within a physician practice, any number of non-licensed staff members can be included under the original physician's subscription at no additional cost.
"The National Healthcare Communications Network will address several areas within the 'Meaningful Use' regulations coming out of Washington, especially in the areas of interoperability, security and access to patient information by qualified sources," said Fred Zolla, CEO of iMedicor. "Initial market research has demonstrated to our partners and to us, internally, that an upgrade to the current state of healthcare communications is not only needed, but also highly desirable throughout the medical community. We believe the widespread adoption of The National Healthcare Communication Network by physicians will provide a major step forward in creating interoperable HIPAA-compliant communications throughout the healthcare community."
iMedicor expects a 20 percent early adoption rate over the next several months with consistent growth on a month-to-month basis as the transition from a paper to a digital medical record system becomes a reality.
http://www.marketwire.com/press-release/iMedicor-Launches-Phase-I-of-The-National-Healthcare-Communications-Network-1315407.htm
CorMedix to present at Rodman & Renshaw Conference
BRIDGEWATER, N.J. --(Business Wire)--
CorMedix Inc. a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced it is scheduled to present at the Rodman & Renshaw Annual Global Investment Conference on September 15, 2010, at 11:40 AM ET, in the Fahnestock Salon, 5th Floor, at the New York Palace Hotel in New York.
Mr. John Houghton, President and CEO of CorMedix, will provide an overview of the Company's product pipeline, clinical development status, and upcoming milestones.
Mr. Houghton's presentation will be webcast live and archived for 90 days on CorMedix's website at: www.cormedix.com.
http://technews.tmcnet.com/news/2010/09/03/4990687.htm
Part 2 of Access C.E.O. Jeff Davis interview.
http://www.accesspharma.com/newsroom/q-a-with-access-pharmaceuticals-ceo-jeffrey-b-davis-part-2-cobalamin-prolindac-and-thiarabine/
Highlights:
Access recently announced an agreement to make an oral formulation of a large drug on the market, which sells close to $1 billion annually in the injectable form, and could be large in an oral form.
The Cobalamin (B-12) technology can also be used to make current drugs more targeted in their application.
With ProLindac, Access simply took the same active drug in Sanofi’s Eloxatin, called DACH platinum, and came up with an innovative delivery mechanism that enables us to deliver more DACH platinum to the patient, in a more tolerable way. It’s a traditional “drug delivery” strategy, using Access proprietary polymer delivery platform.
sleep well......right through September.
I would compare it to "the calm before the storm". Its going to be an exciting next few weeks, thats for sure.
Griffin Securities Initiates Research Coverage on CorMedix
http://www.businesswire.com/news/home/20100824006221/en
SEC shows iMedicor is undervalued according to 8-K report
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=7119303
ACCP Presents at American Chemical Society Annual Fall Meetings.
Director of Chemistry and Quality, Dr. Ric Zarzycki will give an invited presentation today on the Company's Cobalamin nanoparticle technology at a thought-leadership symposium being held at the American Chemical Society's ("ACS") 240th National Meeting & Exposition, at Boston Convention and Exhibition Center in Boston, Massachusetts, August 22-26, 2010. The conference symposium titled, "Multifunctional Nanoparticles for Drug Delivery and Imaging", will focus on the advancement of nanotechnology in the pharmaceutical and diagnostic industries. Dr. Zarzycki will highlight the distinct characteristics of Access' Cobalamin nanotechnology and the potential key role it will play in the future treatment of various diseases.
http://ca.biz.yahoo.com/prnews/100824/aq54126.html?.v=1
Neutrolin Patent Obtained
CorMedix, obtained U.S. Patent No. 7,696,182, which claims cover the use of Neutrolin® for preventing infection and clotting in hemodialysis catheters. Neutrolin® is an antimicrobial/anticoagulant liquid, comprising taurolidine, that “locks” a patient’s chronic central venous catheter between hemodialysis sessions to keep it free of CRBI and clotting.
It will rebound, it is just a matter of when. Hopefully it will be sooner than later because people are more than ready for some real positive results to keep the haters at bay.
Highlights.
-- Added to Russell Microcap® Index
-- Dosed First Patient in Phase II Clinical Trial of CRMD001
-- Additional United States Patent Issued for Neutrolin® (CRMD003) to Prevent Catheter Related Bloodstream Infections (“CRBI”) and Clotting in Hemodialysis Catheters
*New* Update to Zacks Report issued 8/19. Enjoy!
http://www.proactivenewsroom.com/access-pharma-blog/bid/50024/Zacks-Issues-Update-on-their-Outperform-Research-Report-on-Access-Pharmaceuticals-OTCBB-ACCP
Very Soon, I hope. For all our sakes.
Divine Skin Announces Record Quarterly Revenue of $1.3 Million, Up 30% From Q1 2010, Up 78% From Q2 in 2009
http://ih.advfn.com/p.php?pid=nmona&article=44029810&symbol=DSKX
Great Question!
Divine Skin Initiated at Outperform by Zacks Investment Research
MIAMI BEACH, Fla., June 14, 2010 / DIVINE SKIN INC. (OTC Bulletin Board: DSKX), a newly public cosmeceutical developer specializing in topical skin care and hair regrowth, announced that Zacks Investment Research had initiated coverage of the company with an "outperform" recommendation and a six-month target price of $0.50, covered by Analyst Claudio Freitas, CFA.
Divine Skin grew quickly without investment capital until 2009, when it conducted its first private placement. It began trading May 20th, 2010.
The company's strategy is to combine active ingredients that already have US Food and Drug Administration monographs, thus avoiding lengthy approvals while achieving efficacy and delivering new products quickly. The company's first brand, DS Laboratories, established itself with comprehensive minoxidil-based and minoxidil-free products.
Last week, DS Laboratories announced a new agreement for its DS Laboratories brand to supply hair-growth products through Premier Salons, one of North America's largest chains, with about 3,000 locations. It also announced the distribution of its DS Laboratories brand to Fantastic Sams chain, with more than 1,300 franchised salons locations in the United States. So far demand has exceeded expectations.
The full report can be viewed at: http://www.proactivenewsroom.com/ds-laboratories-inc
Good Morning Everyone. Enjoy your Day!
I guess Catbull saw it, Lol. Well Played!
Has anyone seen this news this morning?
http://www.earthtimes.org/articles/press/form-strategic-alliance,1423594.html
HAUPPAUGE, NY - 08/16/10 - Patient Access Solutions, Inc. (PINKSHEETS: PASO), a leading provider of information technology solutions for the healthcare industry announced today a partnership with iMedicor (OTCBB: VMCI). The partnership will provide a complementary synergy of combined products and services that will enable enhanced information exchange capabilities by integrating the iMedicor portal with Patient Access Solution's digital pen technology for the home healthcare industry and robust HIPAA transaction processing and reporting platform.
In addition, Patient Access Solution's 4000+ users will have access to iMedicor's ClearLobby platform that will provide informative, product specific content on new drugs and medical devices enabling users to directly communicate electronically with the manufacturers to order samples, ask questions and set up onsite meetings. ClearLobby establishes an additional revenue driver and value added solution to users by providing access to the recently announced National health information exchange and the National Healthcare Communications Network (NHCN).
Both companies are pleased to announce the Alliance's first opportunity, a 5,000 member healthcare provider group, has entered its implementation phase and scheduled to be live by Q4, 2010. Conservative projections estimate recurring gross annual revenue of over $1,000,000 throughout the PASO user base.
iMedicor's pharma marketing platform, "ClearLobby," offers the first of its kind physician / pharma electronic communication system resulting in interactions that are much more meaningful and efficient. ClearLobby changes the dynamic of these relationships by placing control squarely in the hands of the physician. At the same time, the interaction between the physician and the pharma becomes more cost effective because ClearLobby is able to distribute critical product information and samples directly to the targeted user base.
"We are excited about the strategic partnership we have developed with iMedicor. Their ClearLobby solution interfaced with our technology will provide the healthcare industry with a secure, robust, dynamic information and messaging platform. Being able to develop a mutually beneficial recurring revenue business model creates a win-win for both organizations," said CEO Bruce Weitzberg.
"This alliance is another major step in launching our National Health Information Exchange and will go a long way in supporting and making a reality of the National Healthcare Communication Network," said Fred Zolla, iMedicor's CEO. "This is a great opportunity for two up and coming companies."
Good Morning Den, Lets make this week a Great One!
Thanks Alyce. Have a Great Week.
CorMedix 2nd Qtr 2010 Results.
Second Quarter 2010 Highlights:
-- Added to Russell Microcap(R) Index
-- Dosed First Patient in Phase II Clinical Trial of CRMD001
-- Additional United States Patent Issued for Neutrolin(R) (CRMD003) to Prevent Catheter Related Bloodstream Infections ("CRBI") and Clotting in Hemodialysis Catheters
Financial Results for the Three and Six-Month Periods Ended June 30, 2010
http://www.marketwatch.com/story/cormedix-reports-second-quarter-2010-results-2010-08-12?reflink=MW_news_stmp
well, they did only release it through Clear Lobby & DMS 2 weeks ago to the date. (7/30) I can't see why there wouldn't be a pps increase as the news travels and more people get on board.
It should be there once the testing is over, and Thiarabine transitions to the launch phase of the program. All the infrastructure is in place for a strong launch once the testing has been completed and deemed successful.
Hey Everyone. Happy Friday! I've been out of the loop for the last few days, whats going on?
CorMedix Research report issued by Crystal Research Associates.
http://www.proactivenewsroom.com/Default.aspx?app=LeadgenDownload&shortpath=docs%2fcrystal+research+CRMD_EIO_08-03-2010.pdf
CorMedix Inc. is focused on treating cardiorenal diseases, which entails addressing kidney dysfunction and its cardiovascular complications. CorMedix's lead product candidates are Neutrolin® and deferiprone. Neutrolin® is a catheter lock solution for chronic central venous catheters (CVCs), which are a type of catheter commonly used by hemodialysis patients, among other individuals. Neutrolin®, which has antimicrobial, antifungal, and anticoagulant properties, has been shown to reduce the likelihood of contracting a catheter-related bloodstream infection (CRBSI) by approximately 90% in hemodialysis patients.
To CorMedix's knowledge, there is no approved combined antimicrobial and anticoagulant catheter-locking solution for the prevention of CRBSI in the U.S. today. The Company is working to submit an Investigational Device Exemption (IDE) by the end of 2010, which would enable the start of clinical trials for Neutrolin® in early 2011.
CorMedix is also developing proprietary formulations of deferiprone, a generic pharmaceutical that is commercially available in over 50 countries for removing iron from the body. However, it is not yet marketed in the U.S. CorMedix believes that it possesses novel formulations of immediate and extended-release deferiprone that are not available elsewhere. The FDA has approved Investigational New Drug (IND) applications for deferiprone to prevent contrast-induced nephropathy (CIN) and to treat chronic kidney disease (CKD).
The Company commenced a Phase II biomarker proof-of-concept study of deferiprone in June 2010. In March 2010, CorMedix completed an initial public offering (IPO) on the NYSE Amex for approximately $10.4 million in net proceeds, which the Company primarily intends to use in further clinical development of Neutrolin® and deferiprone.
http://www.businesswire.com/portal/site/home/permalink/?ndmViewId=news_view&newsId=20100810005899&newsLang=en
CorMedix Announces Appointment of Key Positions.
CorMedix Inc. ("CorMedix") , a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced the appointment of Robert D. Hopkins as head of clinical operations and project management and Dilip Wadgaonkar as head of product development and manufacturing.
In these new roles, Dr. Hopkins will be responsible for developing and overseeing the operational strategies for the Company's clinical products, programs, and services and project management to ensure efficient execution of trials, and Mr. Wadgaonkar will be responsible for product development operations and manufacturing, including product/formulation development, planning, implementation and maintenance of analytical methods, technology transfer, processes and operations for new products and technologies.
"Robert Hopkins and Dilip Wadgaonkar bring to CorMedix a wealth of industry knowledge and experience in each of their respective roles, which will be of significant value as we continue to advance our Phase II clinical program of CRMD-001, (a proprietary formulation of deferiprone) for the prevention of contrast-induced acute kidney injury, in addition to preparing our Investigational Device Exemption filing and anticipated subsequent initiation of our pivotal clinical study for CRMD-003, (Neutrolin(R)) for the prevention of catheter related bloodstream infections and clotting in hemodialysis," stated John C. Houghton, president and chief executive officer of CorMedix.
Dr. Hopkins has over a decade of clinical operations and project management experience, with a Doctorate of Veterinary Medicine and Masters of Science Biology. Most recently, Dr. Hopkins served as associate director, project management at Quintiles Transnational, Inc., where he had the responsibility of managing multiple projects, establishing SOPs, policies and procedures for client's clinical programs. Dr. Hopkins' prior experience includes serving as the senior project manager for PRA International, and clinical trial project manager at Pfizer, Inc. Dr. Hopkins will report to Mark T. Houser, M.D. MBA, CorMedix's chief medical officer.
Mr. Wadgaonkar brings to CorMedix over 20 years of formulation and manufacturing experience, with a Ph.D. in Pharmaceutics and a Masters of Science and Pharmacy. Most recently, Mr. Wadgaonkar served as head of research and development at Sun Pharmaceutical Industries Inc., where he was responsible for establishing the research and development manufacturing processes, and supporting the regulatory affairs divisions for all new drug applications. Mr. Wadgaonkar's prior experience includes serving as the vice president of research and development for Interpharm Inc., where he oversaw research and development activities including formulation development, analytical aspects, Abbreviated New Drug Application compilation and technology transfer, in addition to serving at Barr Laboratories, Hoffman La Roche, and Wyeth. Mr. Wadgaonkar will report to John C. Houghton, CorMedix's president and chief executive officer.
About CorMedix
CorMedix Inc. is a pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix's goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications, in effect, treating the kidney to treat the heart. CorMedix currently has several product candidates in development, including its two most advanced product candidates: CRMD-003 (Neutrolin(R)) for the prevention of central venous catheter infection and clotting in hemodialysis; and CRMD-001 (a proprietary formulation of deferiprone) for the prevention of contrast-induced nephropathy in high-risk patients with chronic kidney disease. Please see www.cormedix.com for additional information.
http://www.marketwatch.com/story/cormedix-announces-appointment-of-key-positions-2010-08-10?reflink=MW_news_stmp
Agreed, what I can't understand is how good news comes out of the company, and the bitterness still flows freely from the same people around here. They just aren't on the T.E.A.M.* I guess.
*Together Everyone Achieves More.......
Access' partner iMedicor released some great news today.
http://finance.yahoo.com/news/iMedicor-and-USA-MCO-Announce-iw-1660772586.html?x=0&.v=1
iMedicor and USA MCO Announce Strategic Alliance Agreement to Create the National Healthcare Communications Network
NANUET, NY--(Marketwire - 08/10/10) - iMedicor (OTC.BB:VMCI - News) and USA MCO today announced a new Strategic Alliance creating one of the first nationwide HIPAA compliant National Healthcare Communications Networks (NHCN). USA MCO, one of the nation's largest Managed Care Organizations, will launch a joint awareness campaign with iMedicor to let physicians within its network know that they now have simple access to a national Healthcare Information Exchange (HIE) that will allow physicians to satisfy "meaningful use" regulations. The focus will be the enrollment of USA MCO's 350,000 plus physicians, medical practices and other healthcare providers into the iMedicor HIPAA compliant Health Information Exchange and social community portal. USA MCO represents nearly half of the practicing physicians in the United States.
The alliance provides a major step forward in the Federal government's healthcare initiative focused on a transition to mass adoption of health information technology and the mobilization of personal health information. The USA MCO / iMedicor NHCN will provide full interoperability for secure transport and exchange of medical files, records, images and patient-specific information in the form of secure messaging and standardized data exchange. The NHCN addresses several of the key requirements of "Meaningful Use" regulations involving information exchange. In addition, the network will adhere to the evolving National Health Information Network ("NHIN") Direct protocols and utilize the NHIN Connect interoperability tools. The entire service offering is focused on ease of operation, efficiency of clinical workflow, qualifying for stimulus funding to offset the cost of transitioning from paper to digital medical records systems and provides better healthcare through modern communications.
The network will provide the following:
A National Health Information Exchange
Simplified HIPAA compliant secure messaging to facilitate communication between physicians, staff and patients.
Discreet data exchange through standards recognized by the ONCHIT standards committee.
Build and create community, patient-specific peer collaboration and expansion of referral networks,
Access to educational resources, certified CME, skill level and product / device specific resources.
Unlimited use of the NHCN will only be $19.95 per month per physician. Other Healthcare providers and medical practice staff members connected to the originating physician's subscription will be charged a discounted rate relative to the originating physician's subscription.
Great News Oneforthemoney!
http://www.tradingmarkets.com/news/stock-alert/zzgfv_vmci_imedicor-and-usa-mco-announce-strategic-alliance-agreement-to-create-the-national-healthcare-commun-1100069.html
iMedicor and USA MCO Announce Strategic Alliance Agreement to Create the National Healthcare Communications Network
NANUET, NY, Aug 10, 2010 (MARKETWIRE via COMTEX) --
iMedicor (OTCBB: VMCI | PowerRating) and USA MCO today announced a new Strategic Alliance creating one of the first nationwide HIPAA compliant National Healthcare Communications Networks (NHCN). USA MCO, one of the nation's largest Managed Care Organizations, will launch a joint awareness campaign with iMedicor to let physicians within its network know that they now have simple access to a national Healthcare Information Exchange (HIE) that will allow physicians to satisfy "meaningful use" regulations. The focus will be the enrollment of USA MCO's 350,000 plus physicians, medical practices and other healthcare providers into the iMedicor HIPAA compliant Health Information Exchange and social community portal. USA MCO represents nearly half of the practicing physicians in the United States.
The alliance provides a major step forward in the Federal government's healthcare initiative focused on a transition to mass adoption of health information technology and the mobilization of personal health information. The USA MCO / iMedicor NHCN will provide full interoperability for secure transport and exchange of medical files, records, images and patient-specific information in the form of secure messaging and standardized data exchange. The NHCN addresses several of the key requirements of "Meaningful Use" regulations involving information exchange. In addition, the network will adhere to the evolving National Health Information Network ("NHIN") Direct protocols and utilize the NHIN Connect interoperability tools. The entire service offering is focused on ease of operation, efficiency of clinical workflow, qualifying for stimulus funding to offset the cost of transitioning from paper to digital medical records systems and provides better healthcare through modern communications.
The network will provide the following:
-- A National Health Information Exchange
-- Simplified HIPAA compliant secure messaging to facilitate
communication between physicians, staff and patients.
-- Discreet data exchange through standards recognized by the ONCHIT
standards committee.
-- Build and create community, patient-specific peer collaboration and
expansion of referral networks,
-- Access to educational resources, certified CME, skill level and
product / device specific resources.
Unlimited use of the NHCN will only be $19.95 per month per physician. Other Healthcare providers and medical practice staff members connected to the originating physician's subscription will be charged a discounted rate relative to the originating physician's subscription.
"This is an exceptional opportunity and value to the healthcare community," said George Bogle, Chairman and CEO of USA MCO, "With incentives being planned and developed for participating physicians through the Medicaid / Medicare system that reduces expense through electronic administration and claim support, and the ability of our new network to reduce cost and increase the quality of healthcare in our country, every area of the healthcare community will benefit. We believe that over the next six months a majority of our 350,000 physicians and their practices will engage with the National Health Communications Network."
"After working closely with USA MCO over the past several months, we are very proud that the iMedicor network has been selected by them to create the nation's first HIPAA compliant Healthcare Communication Network," said Fred Zolla, CEO of iMedicor, "This is a major step forward in creating an interoperable, National Health Information Exchange that will support the transition from paper to electronic medical records. Healthcare in our country is State of the Art, yet this sector still uses old and ineffective communications technology, which is the principal barrier to implementing widespread use of electronic medical records. The National Healthcare Communication Network created with this alliance is a major step forward in solving this problem. iMedicor is ready to implement this project as well as several other large scale projects already underway."
About iMedicor:
iMedicor is the only HIPAA-compliant solution for interoperable health information exchange (HIE) that offers a variety of related services to healthcare providers and patients. The iMedicor portal enables physicians, administrators and other qualified healthcare professionals to exchange medical records, files and images in a HIPAA compliant environment and allows disparate EMR (electronic medical record) systems to integrate and share data. iMedicor also delivers important information on new drugs and treatments to its members as well as the members of its syndicated partners through their ClearLobby platform. More information on iMedicor is available at www.imedicor.com
About USA MCO
USA Managed Care Organization (USA) is the largest, most comprehensive, privately-held Preferred Provider Organization in America. Through esteemed panels of preferred providers, ancillary products and specialty services covering the full continuum of care, USA offers innovative alternatives to traditional group health and workers' compensation medical benefits. With a distinct freedom of choice flexibility and a 100% user-friendly platform, USA affords sound solutions through a portfolio of integrated options that are uniquely client driven; focused on the seamless blend of quality care and cost containment.
The statements contained herein, other than historical information, are or may be deemed to be forward-looking statements and involve factors, risks, and uncertainties that may cause actual results in future periods to differ materially from such statements. These factors, risks, and uncertainties include market acceptance of iMedicor's products and services; the nonexclusive and terminable-at-will nature of certain of the company's partnerships and agreements; rapid technological change affecting demand for our products and services; competition from companies providing similar products and services, availability of sufficient financial resources to enable us to expand our operations, as well as other risks detailed from time to time in our filings with the Securities and Exchange Commission.
Sorry to hear of your loss, loannis. I too, received some disturbing news this weekend. It gave me pause and helped me appreciate the little things in life.